Yoshitaka Narita Selected Research

Yoshitaka Narita Research Topics

Disease

72	Neoplasms (Cancer) 11/2022 - 11/2002
57	Glioblastoma (Glioblastoma Multiforme) 11/2022 - 11/2002
47	Glioma (Gliomas) 06/2022 - 09/2005
24	Brain Neoplasms (Brain Tumor) 02/2022 - 09/2005
15	Neoplasm Metastasis (Metastasis) 07/2019 - 04/2005
11	Astrocytoma (Pilocytic Astrocytoma) 07/2021 - 09/2010
8	Germinoma 01/2022 - 01/2010
8	Lymphoma (Lymphomas) 11/2021 - 07/2010
6	Breast Neoplasms (Breast Cancer) 07/2019 - 11/2008
5	Oligodendroglioma 10/2020 - 01/2015
4	Meningioma (Meningiomas) 02/2022 - 06/2013
4	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2022 - 12/2010
3	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 12/2012
3	Lymphopenia (Lymphocytopenia) 12/2021 - 01/2011
2	Carcinogenesis 06/2022 - 12/2017
2	Residual Neoplasm 05/2022 - 01/2013
2	Melanoma (Melanoma, Malignant) 01/2022 - 09/2021
2	Disease Progression 12/2021 - 02/2013
2	Brain Edema (Cerebral Edema) 01/2021 - 01/2015
2	Ependymoma 01/2021 - 12/2018
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 12/2018 - 06/2013
2	Necrosis 12/2016 - 06/2013
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2013 - 12/2012
2	Hematologic Neoplasms (Hematological Malignancy) 10/2013 - 09/2010
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2013 - 09/2010
2	Venous Thromboembolism 06/2013 - 10/2012
2	Hypertension (High Blood Pressure) 06/2013 - 10/2012
2	Leukemia 12/2012 - 09/2010
2	Hepatitis 01/2012 - 01/2011
1	Testicular Neoplasms (Testicular Cancer) 01/2022
1	Ischemic Stroke 12/2021
1	Transient Ischemic Attack 12/2021
1	Thrombocytopenia (Thrombopenia) 12/2021

Drug/Important Bio-Agent (IBA)

26	Temozolomide (Temodar)FDA LinkGeneric 05/2022 - 09/2010
15	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 06/2022 - 03/2012
9	Bevacizumab (Avastin)FDA Link 05/2022 - 10/2012
8	ErbB Receptors (EGF Receptor)IBA 12/2021 - 11/2002
8	RNA (Ribonucleic Acid)IBA 01/2021 - 06/2015
6	DNA (Deoxyribonucleic Acid)IBA 05/2022 - 10/2012
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2010
6	Pharmaceutical PreparationsIBA 01/2021 - 11/2012
5	MethyltransferasesIBA 05/2022 - 10/2012
5	Telomerase (Telomerase Reverse Transcriptase)IBA 02/2022 - 08/2013
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 07/2010
5	Biological ProductsIBA 08/2019 - 11/2008
4	Messenger RNA (mRNA)IBA 10/2020 - 01/2014
4	SteroidsIBA 11/2012 - 04/2005
3	O-(6)-methylguanineIBA 05/2022 - 10/2012
3	eribulin FDA Link 02/2022 - 07/2018
3	Lomustine (CCNU)FDA Link 11/2021 - 01/2013
3	NimustineIBA 11/2021 - 02/2013
3	Progesterone Receptors (Progesterone Receptor)IBA 01/2019 - 11/2008
3	Genetic Markers (Genetic Marker)IBA 04/2018 - 10/2013
3	Procarbazine (Matulane)FDA Link 01/2018 - 01/2013
3	Methotrexate (Mexate)FDA LinkGeneric 10/2017 - 07/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2016 - 10/2012
3	amsonic acid (DAS)IBA 01/2015 - 10/2012
3	Monoclonal AntibodiesIBA 06/2013 - 09/2005
3	TOR Serine-Threonine KinasesIBA 09/2011 - 11/2010
3	epidermal growth factor receptor VIIIIBA 08/2010 - 01/2004
2	AntigensIBA 11/2022 - 01/2022
2	Protein Subunit VaccinesIBA 11/2022 - 01/2011
2	alpha-hydroxyglutarateIBA 06/2022 - 11/2021
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2021
2	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2021 - 01/2014
2	Tumor Biomarkers (Tumor Markers)IBA 01/2021 - 12/2019
2	AntibodiesIBA 01/2021 - 09/2005
2	Transcription Factors (Transcription Factor)IBA 01/2021 - 12/2017
2	MicroRNAs (MicroRNA)IBA 12/2019 - 01/2019
2	Antineoplastic Agents (Antineoplastics)IBA 07/2019 - 07/2018
2	Peptides (Polypeptides)IBA 01/2019 - 01/2011
2	CholesterolIBA 07/2018 - 01/2018
2	Vincristine (Oncovin)FDA LinkGeneric 01/2018 - 01/2013
2	ChromatinIBA 12/2017 - 01/2014
2	GadoliniumIBA 05/2016 - 08/2012
2	Estrogen ReceptorsIBA 11/2013 - 11/2008
2	Alkylating AgentsIBA 10/2013 - 09/2010
2	TransferasesIBA 10/2013 - 01/2012
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 09/2011 - 11/2010
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 09/2011 - 11/2002
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 09/2011 - 11/2010
1	EpitopesIBA 11/2022
1	Coloring Agents (Dyes)IBA 02/2022
1	Glial Fibrillary Acidic ProteinIBA 01/2022
1	S100 Proteins (S 100 Protein)IBA 01/2022
1	Tissue Plasminogen Activator (Alteplase)FDA Link 12/2021
1	Carboxylic AcidsIBA 12/2021
1	depatuxizumab mafodotinIBA 12/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2021
1	Immunoconjugates (Immunoconjugate)IBA 12/2021
1	Alanine Transaminase (SGPT)IBA 12/2021

Therapy/Procedure

44	Radiotherapy 06/2022 - 04/2005
34	Drug Therapy (Chemotherapy) 06/2022 - 09/2005
28	Therapeutics 07/2022 - 12/2008
16	Chemoradiotherapy 05/2022 - 01/2010
4	Aftercare (After-Treatment) 12/2021 - 01/2012
3	Re-Irradiation 05/2022 - 01/2021
3	Craniotomy 06/2021 - 02/2013
2	Terminal Care (Care, Terminal) 12/2020 - 10/2009
2	Adjuvant Chemotherapy 10/2018 - 02/2013